EpilepsyGTx
PrivateLast Round
Series A
Dec 10, 2025
Total Funding Raised
$43M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
EpilepsyGTx operates in Healthcare & Life Sciences and is based in Canterbury. Its latest recorded funding round was a Series A round in December 2025.
EpilepsyGTx is a biotechnology company developing cutting-edge gene therapies to treat focal refractory epilepsy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EpilepsyGTx Comparables
Compare EpilepsyGTx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Latus Bio | 84% | |
| Capsida Biotherapeutics | 81% | |
| Kriya Therapeutics | 80% |
For institutional investors. Book with your work email.
EpilepsyGTx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 10, 2025 | ||||
| Seed | Jun 24, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
EpilepsyGTx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| XGEN Venture | Series A |
| British Business Bank | Series A |
| UCL Business | Seed |
| Albion Capital | Seed |
| Zcube | Seed |
| Health Technology Holding | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 41% MoM.
- Apr 29, 2026
Professor Dimitri Kullmann appointed as the new CSO.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 11, 2026
EpilepsyGTx is developing EPY201, an investigational gene therapy designed for direct delivery to the seizure focus to reduce excessive electrical activity in people with focal refractory epilepsy.
- is_developingSep 9, 2026
EpilepsyGTx collaborates with Viralgen to advance its AAV gene therapy programme for epilepsy, including scalable production of EPY201 for focal refractory epilepsy through Viralgen’s Aava platform, ahead of first-in-human trials in United Kingdom and Spain on Sep 9th '26.
- partners_withSep 9, 2026
On Sep 9th '26, EpilepsyGTx and Viralgen partner to support scalable production of EPY201, an investigational AAV gene therapy for focal refractory epilepsy, ahead of first-in-human clinical trials in Spain.
For institutional investors. Book with your work email.
EpilepsyGTx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EpilepsyGTx's valuation, stock price, and market status.
Is EpilepsyGTx a public or private company?
EpilepsyGTx is a private company.
What is the current stock price of EpilepsyGTx?
EpilepsyGTx is a private company, so its shares have no public market price. Caplight tracks EpilepsyGTx's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EpilepsyGTx worth (valuation)?
Valuation information for EpilepsyGTx is not publicly available.
Can I buy EpilepsyGTx stock?
EpilepsyGTx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EpilepsyGTx's last funding round?
EpilepsyGTx's most recent funding round was Series A on December 10, 2025.
Who are the main investors in EpilepsyGTx?
Key investors in EpilepsyGTx include XGEN Venture, British Business Bank, UCL Business, Albion Capital.
Will EpilepsyGTx IPO soon?
No public IPO plans have been announced for EpilepsyGTx.
How can I track EpilepsyGTx secondary market activity?
Caplight tracks bids, offers, and trades in EpilepsyGTx's shares on secondary markets.